Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.77 |
| ▸ | MEN1 | O00255 | 3/20 | 0.77 |
| ▸ | NPC1 | O15118 | 2/20 | 0.70 |
| ▸ | BRD4 | O60885 | 2/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10790461 | 0.87 | KMT2A (0.77) | KMT2AMEN1NPC1BRD4SMN1; SMN2 | |
| SCHEMBL7945842 | 0.85 | KMT2A (0.74) | KMT2AMEN1NPC1BRD4SMN1; SMN2 | |
| SCHEMBL16232794 | 0.85 | KMT2A (0.69) | KMT2AMEN1NPC1BRD4SMN1; SMN2 | |
| SCHEMBL3207873 | 0.84 | SMN1; SMN2 (0.79) | KMT2AMEN1NPC1BRD4SMN1; SMN2 | |
| SCHEMBL2925817 | 0.84 | KMT2A (0.82) | KMT2AMEN1NPC1BRD4SMN1; SMN2 | |
| SCHEMBL16087965 | 0.84 | KMT2A (0.65) | KMT2AMEN1NPC1BRD4MAPK1 | |
| SCHEMBL8599574 | 0.83 | KMT2A (0.71) | KMT2AMEN1NPC1BRD4SMN1; SMN2 | |
| SCHEMBL4147862 | 0.83 | KMT2A (0.71) | KMT2AMEN1NPC1BRD4L3MBTL1 | |
| SCHEMBL7263748 | 0.83 | KMT2A (0.70) | KMT2AMEN1NPC1BRD4SMN1; SMN2 | |
| SCHEMBL7319045 | 0.83 | KMT2A (0.70) | KMT2AMEN1NPC1BRD4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1635839-B1 | BENZO[4,5]THIENO[2,3-D]PYRIMIDIN-4-ONES AND THEIR USE IN THERAPY | ABBOTT HEALTHCARE PRODUCTS BV (NL) | 2010-09-01 | — | — | EP | disclosed |
| US-7524853-B2 | Compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2009-04-28 | — | — | US | disclosed |
| US-7465739-B2 | Compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-12-16 | — | — | US | disclosed |
| US-20050176742-A1 | Novel compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-08-11 | — | — | US | disclosed |
| US-20050038053-A1 | Novel compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176742-A1 | Novel compounds and their use in therapy | HSD17B11, HSD17B2, HSD17B1 | KMT2A 2945/4885MEN1 2028/4885NPC1 618/4885 |
| US-20050038053-A1 | Novel compounds and their use in therapy | HSD17B11, HSD17B2, HSD17B1 | KMT2A 2945/4885MEN1 2028/4885NPC1 618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.